CD24 and cancer: There have been reports of interactions between Siglec-10 and the highly sialylated version of CD24, therefore Barkal et al. discovered that antibodies against CD24–Siglec-10 interaction increased all CD24-expressing cancer cell lines’ phagocytosis, indicating the clinical potential of this specific immune checkpoint blockade in cancer immunotherapy [86].